“We’ve lost an opportunity to have direct government purchases of hundreds of th...
Can AI diagnose a disease? Are Wegovy's days numbered? And what makes AI halluci...
Illumina shareholders elect one of Carl Icahn's allies to board, but the company...
The FDA delayed its decision on a gene therapy for Duchenne muscular dystrophy a...
Adopting the term "preaddiction" could have potentially disastrous consequences ...
Medicare’s coverage decision has revived longstanding questions about how the fe...
We have an obligation not to leave any useful data on the metaphorical cutting r...
A small club of billionaires is using unorthodox tactics — and piles of cash and...
A new study found that ketamine performs at least as well as ECT, the current go...
Matt Eyles, who led AHIP for five years, is leaving the group. His departure sur...
Boston Scientific is scrapping its $230 million plan to buy a majority stake in ...
Annexon's trial of an eye disease drug missed by a mile. The company saw a bull'...
Immunotherapy turned brain cancers from ‘cold’ to ‘hot’ in mouse study, as clini...
The Biden administration wants to help states control Medicaid prescription drug...
Daniel Cleggett has long been a lightning rod in the addiction recovery communit...
The administration is planning a yearly audit to verify prices drugmakers charge...
